Key result
Temporary cessation and HF therapy reverse trastuzumab-induced cardiotoxicity, allowing safe resumption after an asymptomatic LVEF drop.
Case Report (n=1)
No
This case report illustrates that trastuzumab-induced asymptomatic LVEF decline can be reversed with temporary drug cessation and standard heart failure therapy, permitting safe reintroduction of trastuzumab under close echocardiographic and pharmacovigilance monitoring.
Answers are grounded in this paper and cite their sources.
Supports reversibility of asymptomatic trastuzumab-induced LVEF decline; leaves open generalizability beyond this single case.
METHODS: Cell survival was measured using MTT assay. Apoptosis-related proteins were observed using western blot analysis. Apoptosis was detected with flow cytometric analysis and by Hoechst 33258 staining. The mitochondrial membrane potential was observed with flow cytometric analysis. RESULTS: The ability of BCSCs to propagate decreased gradually along the passages and was completely lost at the fifth passage [0.1 μmol/L mitomycin C (MMC) with 5 μmol/L curcumin in MCF-7 and 0.5 μmol/L MMC with 5 μmol/L curcumin in MDA-MB-231 cells]. Curcumin combined with MMC treatment significantly decreased the levels of antiapoptotic Bcl-2 and Bcl-w expression, increased the levels of proapoptotic Bax, Bak, Bad, Bik, and Bim expression, and activated caspase-3 and caspase-9 in MCF-7 BCSCs. In the presence of Bcl-2 siRNA, the apoptosis rate increased by 15% in cells treated with curcumin and MMC. The mitochondrial membrane potential decreased by approximately 20% in MCF-7 BCSCs undergoing the combination treatment of curcumin and MMC. The combination-induced decrease in Bcl-2 was regulated by the presence of the Wnt-specific inhibitor PFK115-584 and PI3k inhibitor LY294002. CONCLUSIONS: Our study indicates that curcumin might represent a novel therapeutic agent for treating breast cancer chemoresistance induced by MMC.
No takes yet. Share an insight, caveat, or question.
Amar et al. (2019) conducted a case report in HER2-positive, hormone receptor-negative stage IIB (T2N1M0) left invasive ductal breast cancer with trastuzumab-induced cardiotoxicity (n=1). Trastuzumab (with temporary discontinuation and heart failure therapy upon cardiotoxicity) was evaluated on Left ventricular ejection fraction (LVEF) / reversible cardiotoxicity. Trastuzumab monotherapy was associated with an asymptomatic 17.9% LVEF drop (to 49%) that reversed to 62% after 1.5 months of temporary cessation and heart failure therapy, allowing safe resumption.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: